indazoles has been researched along with Erythrocytosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bari, A; Caputo, F; Cerma, K; Dominici, M; Fanelli, M; Gelsomino, F; Pozzi, S | 1 |
| Boyle, H; Brachet, PE; Coquan, E; Dugué, AE; Escudier, B; Helissey, C; Johnson, AC; Joly, F; Laguerre, B; Matias, M; Molinier, A; Mourey, L | 1 |
1 review(s) available for indazoles and Erythrocytosis
| Article | Year |
|---|---|
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature.
Topics: Angiogenesis Inhibitors; Fibroma; Fibrosarcoma; Humans; Indazoles; Male; Middle Aged; Polycythemia; Protein Kinase Inhibitors; Pyrimidines; Soft Tissue Neoplasms; Sulfonamides | 2021 |
1 other study(ies) available for indazoles and Erythrocytosis
| Article | Year |
|---|---|
Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hemoglobins; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Polycythemia; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |